Affinity DataKi: 0.300nM IC50: 0.980nMAssay Description:Receptor Source: Human recombinant expressed in CHO cells Radioligand: [3H]Spiperone (20-60 Ci/mmol) Control Compound: Haloperidol Incubatio...More data for this Ligand-Target Pair
Affinity DataKi: 0.300nMAssay Description:Dopamine, D2S: Materials and Methods: Receptor Source: Human recombinant expressed in CHO cells Radioligand: [3H]Spiperone (20-60 Ci/mmol) C...More data for this Ligand-Target Pair
Affinity DataKi: 0.610nM IC50: 1.96nMAssay Description:Receptor Source: Human recombinant expressed in CHO cells Radioligand: [3H]Spiperone (20-60 Ci/mmol) Control Compound: Haloperidol Incubatio...More data for this Ligand-Target Pair
Affinity DataKi: 0.610nMAssay Description:Dopamine, D2S: Materials and Methods: Receptor Source: Human recombinant expressed in CHO cells Radioligand: [3H]Spiperone (20-60 Ci/mmol) C...More data for this Ligand-Target Pair
Affinity DataKi: 0.650nM IC50: 0.970nMAssay Description:Receptor Source: Human recombinant expressed in HEK-293 cells Radioligand: [3H]-8-OH-DPAT (221 Ci/mmol) Control Compound: 8-OH-DPAT Incubati...More data for this Ligand-Target Pair
Affinity DataKi: 0.650nMAssay Description:Serotonin, 5HT1A:Receptor Source: Human recombinant expressed in HEK-293 cellsRadioligand: [3H]-8-OH-DPAT (221 Ci/mmol)Control Compound: 8-OH-DPATInc...More data for this Ligand-Target Pair
Affinity DataKi: 0.800nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 0.800nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 0.910nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 1nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
Affinity DataKi: 1.16nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 1.16nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 1.19nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 1.19nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 1.40nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 1.40nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 1.5nM IC50: 2.25nMAssay Description:Receptor Source: Human recombinant expressed in HEK-293 cells Radioligand: [3H]-8-OH-DPAT (221 Ci/mmol) Control Compound: 8-OH-DPAT Incubati...More data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
Affinity DataKi: 1.5nMAssay Description:Serotonin, 5HT1A:Receptor Source: Human recombinant expressed in HEK-293 cellsRadioligand: [3H]-8-OH-DPAT (221 Ci/mmol)Control Compound: 8-OH-DPATInc...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 2nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 2.30nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
Affinity DataKi: 2.38nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 2.38nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 2.39nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 2.39nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 2.79nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
Affinity DataKi: 2.99nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 2.99nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 3.31nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 3.31nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 3.80nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 3.80nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 5.45nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 5.45nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 5.49nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 5.70nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
Affinity DataKi: 7.20nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 8.10nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 10.6nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 11nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 11.0nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 12.7nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 12.7nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 13.4nMAssay Description:The monoamine transporters inhibitory activities of selected compounds cycloalkylmethylamine derivatives comprising Formula (I) are reported herein. ...More data for this Ligand-Target Pair
Affinity DataKi: 14.8nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 14.8nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 17.1nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
TargetSodium-dependent noradrenaline transporter(Homo sapiens (Human))
Reviva Pharmaceuticals
US Patent
Reviva Pharmaceuticals
US Patent
Affinity DataKi: 17.1nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair
Affinity DataKi: 18.8nMAssay Description:The compounds were evaluated using well established radioligand binding assays protocols (Galli, A. et al., J. Exp. Biol. 1995, 198, 2197-2212; Giros...More data for this Ligand-Target Pair
Affinity DataKi: 18.8nMAssay Description:The monoamine transporters inhibitory activities of selected cycloalkylmethylamines of Formula (I) are reported herein. The compounds were evaluated ...More data for this Ligand-Target Pair